Free Trial

Y Intercept Hong Kong Ltd Purchases Shares of 8,430 Medpace Holdings, Inc. (NASDAQ:MEDP)

Medpace logo with Medical background

Y Intercept Hong Kong Ltd bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,430 shares of the company's stock, valued at approximately $2,814,000.

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its stake in Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company's stock valued at $230,000 after buying an additional 26 shares during the period. Wealth Alliance increased its stake in shares of Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company's stock worth $399,000 after acquiring an additional 27 shares during the last quarter. Centaurus Financial Inc. raised its holdings in shares of Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after acquiring an additional 29 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in Medpace by 0.7% during the second quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company's stock valued at $1,787,000 after purchasing an additional 32 shares during the last quarter. Finally, Lindenwold Advisors INC grew its stake in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock valued at $676,000 after purchasing an additional 32 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 2.9 %

MEDP stock traded down $10.27 during mid-day trading on Tuesday, reaching $341.95. 305,534 shares of the stock traded hands, compared to its average volume of 282,743. The business has a 50-day moving average of $338.68 and a two-hundred day moving average of $368.95. The firm has a market capitalization of $10.63 billion, a PE ratio of 29.94, a P/E/G ratio of 1.94 and a beta of 1.37. Medpace Holdings, Inc. has a 52 week low of $277.72 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. During the same quarter last year, the firm posted $2.22 EPS. The company's revenue was up 8.3% on a year-over-year basis. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. TD Cowen reduced their price target on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Redburn Atlantic initiated coverage on shares of Medpace in a research note on Monday, October 14th. They issued a "buy" rating and a $404.00 target price for the company. Baird R W downgraded shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and cut their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. Finally, StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $380.56.

View Our Latest Stock Analysis on Medpace

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Recommended Stories

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Should you invest $1,000 in Medpace right now?

Before you consider Medpace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.

While Medpace currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Unveils Game-Changing Tech, But Stock Dips
Rivian Stock Surge Analysis: Long-Term Potential or Short-Term Play?
The Future of Healthcare: 3 AI Stocks Leading the Way

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines